NCT03420508Active, not recruitingPhase 2
Treating Patients With Melanoma and ALK Alterations With Ensartinib
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
The purpose of this study is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma with a particular type of abnormality.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 29 Jan 2018
- Start date
- 10 Jan 2018
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Melanoma
- NCT number
- NCT03420508
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 18
- From 10 Jan 2018 to the primary completion date, 31 Jan 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.